@article{StephanWeiherSchmidtWolf2017,
  author    = {David Stephan and Hans Weiher and Ingo G. H. Schmidt-Wolf},
  title     = {CIK Cells and HDAC Inhibitors in Multiple Myeloma},
  series   = {International Journal of Molecular Sciences},
  volume    = {18},
  number    = {5},
  publisher = {MDPI},
  address   = {Basel},
  issn      = {1422-0067},
  doi       = {10.3390/ijms18050945},
  url       = {https://nbn-resolving.org/urn:nbn:de:hbz:1044-opus-30480},
  year      = {2017},
  abstract  = {Multiple myeloma is the second most common hematological malignancy. Despite all the progress made in treating multiple myeloma, it still remains an incurable disease. Patients are left with a median survival of 4-5 years. The combined treatment of multiple myeloma with histone deacetylase inhibitors and cytokine-induced killer cells provides a promising targeted treatment option for patients. This study investigated the impact of a combined treatment compared to treatment with histone deacetylase inhibitors. The experiments revealed that a treatment with histone deacetylase (HDAC) inhibitors could reduce cell viability to 59\% for KMS 18 cell line and 46\% for the U-266 cell line. The combined treatment led to a decrease of cell viability to 33\% for KMS 18 and 27\% for the U-266 cell line, thus showing a significantly better efficacy than the single treatment.},
  language  = {en}
}